AVC-S 101
Alternative Names: AVC-S-101Latest Information Update: 07 Oct 2025
At a glance
- Originator Avidicure
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bladder cancer; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 23 Jul 2025 Preclinical trials in Bladder cancer in Netherlands (Parenteral), prior to July 2025 (Avidicure pipeline, July 2025)
- 23 Jul 2025 Preclinical trials in Endometrial cancer in Netherlands (Parenteral), prior to July 2025 (Avidicure pipeline, July 2025)
- 23 Jul 2025 Preclinical trials in Head and neck cancer in Netherlands (Parenteral), prior to July 2025 (Avidicure pipeline, July 2025)